Sushovan Guha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sushovan Guha has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Nirav Thosani
Stanford University
11 shared publications Zhimin Tong
8 shared publications- Enrique Rozengurt
University of California, Los Angeles 2 Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine Los Angeles, California
7 shared publications Yoichi Matsuo
Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, Texas
7 shared publicationsNobuo Ochi
6 shared publicationsBharat B. Aggarwal
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
5 shared publications
Latest Publications
- Open Access
- 4 May 2017
- Published by Symbiosis Group in Journal of Gastroenterology, Pancreatology & Liver Disorders
- Vol. 4 (3) , 1
Technical challenges during therapeutic ERCP in a patient with Situs Inversus Totalis
- 4 May 2017
- Published by Symbiosis Group in Journal of Gastroenterology, Pancreatology & Liver Disorders
- Vol. 4 (3) , 1
Open AccessTechnical challenges during therapeutic ERCP in a patient with Situs Inversus Totalis
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB444
Mo1161 Is Suspending Heparin-Based Anticoagulation Necessary Prior to Percutaneous Endoscopic Gastrostomy Procedure?
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB444
Mo1161 Is Suspending Heparin-Based Anticoagulation Necessary Prior to Percutaneous Endoscopic Gastrostomy Procedure?
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB450-AB451
Mo1176 Risk of Bleeding in Patients on Uninterrupted Warfarin or Novel Oral Anticoagulants Undergoing Percutaneous Endoscopic Gastrostomy (PEG)
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB450-AB451
Mo1176 Risk of Bleeding in Patients on Uninterrupted Warfarin or Novel Oral Anticoagulants Undergoing Percutaneous Endoscopic Gastrostomy (PEG)
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB462
Mo1206 Safety Profile of Percutaneous Endoscopic Gastrostomy (PEG) in Geriatric Patients: A Retrospective Study
- 1 May 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (5) , AB462
Mo1206 Safety Profile of Percutaneous Endoscopic Gastrostomy (PEG) in Geriatric Patients: A Retrospective Study
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB116-AB117
166 Natural Language Processing (NLP) As an Alternative to Manual Reporting of Colonoscopy Quality Metrics
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB116-AB117
166 Natural Language Processing (NLP) As an Alternative to Manual Reporting of Colonoscopy Quality Metrics
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
537 Circulating MicroRNAs in Pancreatic Juice As Biomarkers of Pancreatic Cancer
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
537 Circulating MicroRNAs in Pancreatic Juice As Biomarkers of Pancreatic Cancer
- 25 September 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (3) , 768-776
Percutaneous Endoscopic Gastrostomy in Cancer Patients: Predictors of 30-Day Complications, 30-Day Mortality, and Overall Mortality
Cancer patients benefit from percutaneous endoscopic gastrostomy (PEG) in many ways including nutritional support and venting in cases of malignant obstruction. Lack of high-quality studies with adequate follow-up has led to limited information regarding risk stratification and predictors of morbidity and mortality. Elucidate predictors of complications and mortality with long-term follow-up in cancer patients undergoing PEG. Retrospective review of all patients undergoing PEG placement at MD Anderson Cancer Center from January 1, 2004 to December 31, 2006. Statistical analysis included descriptive statistics, Kaplan–Meier survival estimates, and Cox proportional hazards regression analyses. A total of 218 subjects underwent PEG. Those with American Society of Anesthesiology (ASA) scores of 4, 4E, or 5E were at significant risk of a major complication in the first 30 days. Multivariate analysis revealed ASA scores ≥4, elevated WBC count, and advanced tumor stage to be independent predictors of mortality in the first 30 days and INR >1.5 and diversion/venting as an indication for PEG placement to be independent predictors of overall mortality. Patients with high baseline illness severity are more likely to have complications and are at increased risk of mortality after PEG. Our study results suggest that particular attention be directed to ASA score, INR, WBC counts, transfusion requirements, presence of advanced malignancies, and the indication for PEG placement when determining risk of complications or death. Patients undergoing venting PEG are expected to have short post-PEG survival but improvement in quality of life likely justifies the risks associated with PEG placement.
- 25 September 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (3) , 768-776
Percutaneous Endoscopic Gastrostomy in Cancer Patients: Predictors of 30-Day Complications, 30-Day Mortality, and Overall Mortality
Cancer patients benefit from percutaneous endoscopic gastrostomy (PEG) in many ways including nutritional support and venting in cases of malignant obstruction. Lack of high-quality studies with adequate follow-up has led to limited information regarding risk stratification and predictors of morbidity and mortality. Elucidate predictors of complications and mortality with long-term follow-up in cancer patients undergoing PEG. Retrospective review of all patients undergoing PEG placement at MD Anderson Cancer Center from January 1, 2004 to December 31, 2006. Statistical analysis included descriptive statistics, Kaplan–Meier survival estimates, and Cox proportional hazards regression analyses. A total of 218 subjects underwent PEG. Those with American Society of Anesthesiology (ASA) scores of 4, 4E, or 5E were at significant risk of a major complication in the first 30 days. Multivariate analysis revealed ASA scores ≥4, elevated WBC count, and advanced tumor stage to be independent predictors of mortality in the first 30 days and INR >1.5 and diversion/venting as an indication for PEG placement to be independent predictors of overall mortality. Patients with high baseline illness severity are more likely to have complications and are at increased risk of mortality after PEG. Our study results suggest that particular attention be directed to ASA score, INR, WBC counts, transfusion requirements, presence of advanced malignancies, and the indication for PEG placement when determining risk of complications or death. Patients undergoing venting PEG are expected to have short post-PEG survival but improvement in quality of life likely justifies the risks associated with PEG placement.